Fortress Biotech, Inc. (NASDAQ:FBIO) Expected to Post Quarterly Sales of $21.79 Million

Wall Street brokerages expect Fortress Biotech, Inc. (NASDAQ:FBIOGet Rating) to report sales of $21.79 million for the current quarter, Zacks reports. Five analysts have provided estimates for Fortress Biotech’s earnings, with estimates ranging from $19.30 million to $25.00 million. Fortress Biotech posted sales of $17.84 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.1%. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Fortress Biotech will report full-year sales of $92.85 million for the current year, with estimates ranging from $76.60 million to $103.17 million. For the next financial year, analysts expect that the company will post sales of $144.70 million, with estimates ranging from $102.70 million to $244.84 million. Zacks’ sales averages are an average based on a survey of research firms that cover Fortress Biotech.

Fortress Biotech (NASDAQ:FBIOGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.10. Fortress Biotech had a negative net margin of 88.31% and a negative return on equity of 32.56%. During the same period last year, the business posted ($0.11) EPS.

Several research firms have commented on FBIO. Zacks Investment Research upgraded Fortress Biotech from a “strong sell” rating to a “hold” rating in a report on Friday, May 13th. Roth Capital reissued a “buy” rating on shares of Fortress Biotech in a research report on Tuesday, March 29th. TheStreet lowered Fortress Biotech from a “c-” rating to a “d+” rating in a research report on Monday, February 14th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $6.00 target price on shares of Fortress Biotech in a research report on Friday, May 13th. Finally, StockNews.com lowered Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Wednesday, May 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $9.50.

NASDAQ:FBIO opened at $0.91 on Wednesday. The stock has a fifty day simple moving average of $1.19 and a 200-day simple moving average of $2.00. Fortress Biotech has a 52-week low of $0.79 and a 52-week high of $4.49. The company has a market capitalization of $97.37 million, a PE ratio of -1.05 and a beta of 2.27. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 0.46.

Several hedge funds have recently made changes to their positions in FBIO. Renaissance Technologies LLC lifted its position in shares of Fortress Biotech by 1,005.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,101,300 shares of the biopharmaceutical company’s stock worth $1,498,000 after buying an additional 1,001,653 shares during the period. Acadian Asset Management LLC grew its stake in shares of Fortress Biotech by 169.1% during the first quarter. Acadian Asset Management LLC now owns 424,693 shares of the biopharmaceutical company’s stock worth $575,000 after purchasing an additional 266,853 shares during the period. Morgan Stanley grew its stake in shares of Fortress Biotech by 768.2% during the second quarter. Morgan Stanley now owns 266,945 shares of the biopharmaceutical company’s stock worth $953,000 after purchasing an additional 236,198 shares during the period. GSA Capital Partners LLP acquired a new position in Fortress Biotech in the first quarter valued at about $277,000. Finally, Wells Fargo & Company MN grew its stake in Fortress Biotech by 293.5% in the fourth quarter. Wells Fargo & Company MN now owns 227,638 shares of the biopharmaceutical company’s stock valued at $569,000 after acquiring an additional 169,790 shares during the period. Institutional investors own 30.92% of the company’s stock.

About Fortress Biotech (Get Rating)

Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne.

Read More

Get a free copy of the Zacks research report on Fortress Biotech (FBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.